A.M. Edwards

The paper curates 222 genes associated with autism spectrum disorder (ASD) using the EAGLE framework, identifying 78 with definitive evidence and highlighting differential expression patterns between ASD and broader neurodevelopmental disorders.

The paper uses high-throughput affinity-selection mass spectrometry to identify protein targets of ToxCast and PFAS compounds, discovering novel interactions and revealing distinct binding patterns of legacy and replacement PFAS.

The paper develops macrocyclic peptides that target HAP40, enabling the study of HTT-HAP40 interactions and their role in Huntington's disease.

This study shows that ABHD2 activity is not required for progesterone-induced Ca2+ influx via CatSper and subsequent motility changes in human sperm.

The paper identifies HR3/RORα as a conserved cholesterol sensor that activates the TOR pathway in Drosophila and human cells, linking cholesterol availability to growth regulation.

The paper develops and validates novel monoclonal antibodies targeting the C-terminal HEAT domain of huntingtin, showing they detect full-length HTT regardless of polyglutamine length or HAP40 interaction.

This study introduces E-ASMS, a method to detect weak binders and assess enantioselectivity, identifying 16 binders across 12 human protein targets with confirmed binding mechanisms.

The paper identifies a small molecule ligand for the HTT-HAP40 complex using AS-MS and validates its binding through multiple techniques, highlighting a druggable interface for HD therapeutics.

The paper establishes a validated antibody platform for ALS research, identifying high-quality antibodies and revealing protein expression patterns in neurological cell types.

This paper identifies and characterizes high-affinity, selective macrocyclic peptide ligands for Huntingtin, enabling structural and functional studies of HTT and its complex with HAP40.

This study determines the structure of mouse BOCT1 and reveals its function as an independent iron transporter using cryo-EM and functional assays.

The paper determines the structural basis of TMPRSS11D autocleavage activation and shows that nafamostat mesylate is cleaved by TMPRSS11D, reducing its efficacy as a protease inhibitor.

The paper evaluates computational hit-finding methods for targeting the WDR domain of LRRK2, a Parkinson's disease protein, finding that diverse strategies yielded weakly potent compounds.

The paper develops a resource for discovering ligands for WDR proteins using experimental and computational methods, leading to the identification of drug-like ligands for 9 out of 20 targets.

Over half of 614 commercial antibodies for 65 human neuroscience proteins failed a knockout-controlled assay, yet most targets had a well-performing antibody; recombinants performed best.

The paper validates antibodies against the C9ORF72 protein, finding one specific monoclonal antibody and highlighting issues with others used in published studies.